One of the recent breakthroughs in cancer research is the identification of activating mutations in various receptor tyrosine kinase(RTK) pathways in many cancers including colorectal cancer(CRC). We hypothesize that, alternative to mutations, overexpression of various oncogenic RTKs may also underpin CRC pathogenesis, and different RTK may couple with distinct downstream signaling pathways in different subtypes of human CRC. By immunohistochemistry, we show here that RTK members ErbB2, ErbB3 and c-Met were in deed differentially overexpressed in colorectal cancer patient samples leading to constitutive activation of RTK signaling pathways. Using ErbB2 specific inhibitor Lapatinib and c-Met specific inhibitor PHA-665752, we further demonstrated that this constitutive activation of RTK signaling is necessary for the survival of colorectal cancer cells. Furthermore, we show that RTK overexpression pattern dictates the use of downstream AKT and/or MAPK pathways. Our data are important additions to current oncogenic mutation models, and further explain the clinical variation in therapeutic responses of colorectal cancer. Our findings advocate for more personalized therapy tailored to individual patients based on their type of RTK expression in addition to their mutation status.
References
[1]
Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, et al. (2012) Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst 104: 815–840.
[2]
Benson AB, . (2013) Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 11: 141–152; quiz 152.
[3]
Romagnolo DF, Selmin OI (2012) Flavonoids and cancer prevention: a review of the evidence. J Nutr Gerontol Geriatr 31: 206–238.
[4]
Cervantes A (2012) Preoperative chemotherapy for colon cancer is getting closer. Lancet Oncol 13: 1073–1074.
[5]
Foxtrot Collaborative G (2012) Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol 13: 1152–1160.
[6]
Huang S, Holzel M, Knijnenburg T, Schlicker A, Roepman P, et al. (2012) MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling. Cell 151: 937–950.
[7]
Aparicio LA, Valladares M, Blanco M, Alonso G, Figueroa A (2012) Biological influence of Hakai in cancer: a 10-year review. Cancer Metastasis Rev 31: 375–386.
[8]
Jun JI, Lau LF (2011) Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov 10: 945–963.
[9]
Yue P, Zhang X, Paladino D, Sengupta B, Ahmad S, et al. (2012) Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells. Oncogene 31: 2309–2322.
[10]
Gan HK, Burgess AW, Clayton AH, Scott AM (2012) Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res 72: 2924–2930.
[11]
Lefebvre J, Ancot F, Leroy C, Muharram G, Lemiere A, et al. (2012) Met degradation: more than one stone to shoot a receptor down. FASEB J 26: 1387–1399.
[12]
Cecchi F, Rabe DC, Bottaro DP (2012) Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets 16: 553–572.
[13]
Kielbowna L, Jedrzejowska I (2012) How is myogenesis initiated in chordates? Folia Biol (Krakow) 60: 107–119.
[14]
Peters S, Adjei AA (2012) MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 9: 314–326.
[15]
Gao JJ, Inagaki Y, Xue X, Qu XJ, Tang W (2011) c-Met: A potential therapeutic target for hepatocellular carcinoma. Drug Discov Ther 5: 2–11.
[16]
Liu X, Newton RC, Scherle PA (2011) Development of c-MET pathway inhibitors. Expert Opin Investig Drugs 20: 1225–1241.
[17]
Sgambato A, Casaluce F, Maione P, Rossi A, Rossi E, et al. (2012) The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer. Curr Pharm Des 18: 6155–6168.
[18]
Yap TA, Sandhu SK, Alam SM, de Bono JS (2011) HGF/c-MET targeted therapeutics: novel strategies for cancer medicine. Curr Drug Targets 12: 2045–2058.
[19]
Brugger W, Thomas M (2012) EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment. Lung Cancer 77: 2–8.
[20]
Fafalios A, Ma J, Tan X, Stoops J, Luo J, et al. (2011) A hepatocyte growth factor receptor (Met)-insulin receptor hybrid governs hepatic glucose metabolism. Nat Med 17: 1577–1584.
[21]
Fan W, Tang Z, Yin L, Morrison B, Hafez-Khayyata S, et al. (2011) MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents. Cancer Res 71: 4494–4505.
[22]
Zhang L, Virani S, Zhang Y, Bhojani MS, Burgess TL, et al. (2011) Molecular imaging of c-Met tyrosine kinase activity. Anal Biochem 412: 1–8.
[23]
Muzny DM, Bainbridge MN, Chang K, Dinh HH, Drummond JA, et al. (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330–337.
[24]
Bentivegna S, Zheng J, Namsaraev E, Carlton VE, Pavlicek A, et al. (2008) Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD). Hum Mutat 29: 441–450.
[25]
Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, et al. (2013) Oncogenic ERBB3 mutations in human cancers. Cancer Cell 23: 603–617.
[26]
Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, et al. (2005) Colorectal cancer: mutations in a signalling pathway. Nature 436: 792.
[27]
Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318: 1108–1113.
[28]
Gajria D, Chandarlapaty S (2011) HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 11: 263–275.
[29]
Gutierrez C, Schiff R (2011) HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 135: 55–62.
[30]
Chow A, Arteaga CL, Wang SE (2011) When tumor suppressor TGFbeta meets the HER2 (ERBB2) oncogene. J Mammary Gland Biol Neoplasia 16: 81–88.
[31]
Miller TW, Balko JM, Arteaga CL (2011) Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 29: 4452–4461.
[32]
Osborne CK, Schiff R (2011) Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62: 233–247.
